Acalabrutinib’s enhanced specificity for BTK and/or less inhibition of C-terminal Src kinase may cause lower off-target effects, explaining the lower incidence of atrial fibrillation in our cohort of patients. This evidence concerns the gene BTK and atrial fibrillation.